{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:54:37Z","timestamp":1790250877262,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","dmidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.diagmicrobio.2017.11.001","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T07:45:15Z","timestamp":1510299915000},"page":"186-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["In vitro activity of tedizolid against the Mycobacterium abscessus complex"],"prefix":"10.1016","volume":"90","author":[{"given":"Fabrice","family":"Compain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Soroka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Heym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Dorch\u00e8ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Dub\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0005","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1183\/09031936.00041314","article-title":"In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis","volume":"44","author":"Bolhuis","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0010","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1128\/AAC.01569-09","article-title":"Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges","volume":"54","author":"Brown","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0015","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/CMR.15.4.716-746.2002","article-title":"Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria","volume":"15","author":"Brown-Elliott","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0020","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/JCM.00274-17","article-title":"In vitro susceptibility testing of tedizolid against nontuberculous mycobacteria","volume":"55","author":"Brown-Elliott","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0025","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.aaf8156","article-title":"Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium","volume":"354","author":"Bryant","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0030","series-title":"CLSI Doc","first-page":"M24-A2","article-title":"Susceptibility testing of mycobacteria, Nocardiae, and other aerobic Actinomycetes: approved standard","author":"Clinical and Laboratory Standards Institute (CLSI), Wayne, PA","year":"2011"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0035","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s10156-008-0651-Y","article-title":"Mycobacterium abscessus from respiratory isolates: activities of drug combinations","volume":"15","author":"Cremades","year":"2009","journal-title":"J Infect Chemother"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2017.11.001_bb0040","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jcf.2017.04.013","article-title":"Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients","volume":"16","author":"DaCosta","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0045","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0050","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1128\/AAC.00502-11","article-title":"Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model","volume":"55","author":"Drusano","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0055","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/phar.1337","article-title":"Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug","volume":"34","author":"Flanagan","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0060","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.det.2015.03.017","article-title":"Nontuberculous mycobacteria: skin and soft tissue infections","volume":"33","author":"Gonzalez-Santiago","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0065","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0070","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/jac\/dkx097","article-title":"Correction of myelotoxicity after switch of linezolid to tedizolid for prolonged treatments","volume":"72","author":"Khatchatourian","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0075","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0080","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/jac\/dkw022","article-title":"Bactericidal and intracellular activity of \u03b2-lactams against Mycobacterium abscessus","volume":"71","author":"Lefebvre","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0085","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/jac\/dkp267","article-title":"Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines","volume":"64","author":"Lemaire","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0090","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/jac\/dkw206","article-title":"Characterization of the haematological profile of 21 days of tedizolid in healthy subjects","volume":"71","author":"Lodise","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0095","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/JCM.01274-10","article-title":"Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus (sensu lato) strains","volume":"49","author":"Macheras","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb9000","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1128\/AAC.02448-14","article-title":"Lack of antimicrobial bactericidal activity in Mycobacterium abscessus","volume":"58","author":"Maurer","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1476-0711-13-13","article-title":"Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages","volume":"13","author":"Molina-Torres","year":"2014","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0105","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1080\/14787210.2016.1238304","article-title":"Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment","volume":"14","author":"Mougari","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0110","article-title":"In vitro activities of LCB 01-0648, a novel oxazolidinone, against gram-positive bacteria","volume":"22","author":"Oh","year":"2017","journal-title":"Mol Basel Switz"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jcf.2014.08.002","article-title":"Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia","volume":"14","author":"Qvist","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijantimicag.2012.03.006","article-title":"Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers","volume":"40","author":"Sahre","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0125","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1128\/AAC.00228-09","article-title":"In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent","volume":"53","author":"Schaadt","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0130","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1128\/AAC.03950-14","article-title":"Lack of neuropathological changes in rats administered tedizolid phosphate for nine months","volume":"59","author":"Schlosser","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0135","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1128\/AAC.00859-08","article-title":"In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains","volume":"52","author":"Shaw","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0140","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1128\/AAC.01691-15","article-title":"Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis","volume":"60","author":"Tasneen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0145","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1128\/AAC.00763-06","article-title":"In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria","volume":"50","author":"Vera-Cabrera","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0150","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1128\/AAC.47.12.3789-3794.2003","article-title":"Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose","volume":"47","author":"Wagenlehner","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0155","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jac\/dkw484","article-title":"Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity","volume":"72","author":"Yuste","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0160","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1128\/AAC.02410-14","article-title":"In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis","volume":"58","author":"Zhang","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0165","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ijantimicag.2016.12.003","article-title":"In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense","volume":"49","author":"Zhang","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijid.2016.08.027","article-title":"Interactions of linezolid and second-line anti-tuberculosis agents against multidrug-resistant Mycobacterium tuberculosis in vitro and in vivo","volume":"52","author":"Zhao","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2017.11.001_bb0175","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tube.2015.07.003","article-title":"Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates","volume":"95","author":"Zou","year":"2015","journal-title":"Tuberculosis (Edinburgh, Scotland)"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317303528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889317303528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T04:35:26Z","timestamp":1535258126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889317303528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0732889317303528"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.11.001","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of tedizolid against the Mycobacterium abscessus complex","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2017.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}